Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$19.66
$0.311.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.39% | 62.57% | 58.73% | 49.34% | 39.61% |
| Total Depreciation and Amortization | -0.44% | 0.73% | 7.67% | 11.99% | 13.22% |
| Total Amortization of Deferred Charges | 591.33% | 424.92% | 254.92% | 46.84% | -22.68% |
| Total Other Non-Cash Items | -12.80% | -5.34% | 2.19% | -20.03% | -16.31% |
| Change in Net Operating Assets | 135.66% | 90.83% | 44.94% | -57.75% | -439.25% |
| Cash from Operations | 98.49% | 85.23% | 67.83% | 34.46% | 5.12% |
| Capital Expenditure | 85.38% | 47.87% | 68.74% | 68.71% | 52.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 83.33% | 40.21% | -100.31% | -100.17% | -100.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -85.92% | -95.92% | -89.88% | -89.27% | -83.86% |
| Repurchase of Common Stock | 47.83% | 99.48% | 99.66% | 99.70% | 99.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -871.44% | -323.39% | -512.61% | -508.87% | 246.65% |
| Cash from Financing | -62.99% | -62.17% | -60.96% | -60.52% | -70.63% |
| Foreign Exchange rate Adjustments | 30.00% | -588.15% | 439.69% | 327.19% | 73.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.47% | 130.04% | 58.12% | -2,308.47% | -434.49% |